The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial

What Was Tested

The paper reports a study of Insulin Aspart and NPH Insulin (isophane), published as a randomized controlled trial.

Who Took Part

The abstract describes 30 patients taking part.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Open-label, three-arm, 24-week trial; 582 insulin-naïve patients were randomized to twice-daily BIAsp 30+sitagliptin (BIAsp BID+Sit), once-daily BIAsp 30+sitagliptin (BIAsp QD+Sit) or twice-daily BIAsp 30 without sitagliptin (BIAsp BID), all with metformin.

How the Study Was Run

In design terms this was a randomized and open-label study.

The patients were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

Being open-label, the Insulin Aspart study did not mask who received what.

What Was Measured

The subject headings attached to it are Asia, Australia, Biomarkers, Biphasic Insulins, Blood Glucose, Cost-Benefit Analysis and Diabetes Mellitus, Type 2.

Author keywords: Randomized trial, Sitagliptin and Type 2 diabetes.

What This Means in Plain Language

The paper is a randomized and open-label study of Insulin Aspart and NPH Insulin (isophane) in 30 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Primary care diabetes), a journal based in England.

More context: the Insulin Aspart compound page and the NPH Insulin (isophane) compound page.